Rxi Pharmaceuticals Corp. Daily Stock Analysis

Daily Stock Analysis, RXII, Rxi Pharmaceuticals Corp, priceseries

Rxi Pharmaceuticals Corp. Daily Stock Analysis
Stock Information
Open
0.33
Close
0.33
High
0.33
Low
0.32
Previous Close
0.33
Daily Price Gain
0.00
YTD High
107400.00
YTD High Date
Mar 14, 2013
YTD Low
0.31
YTD Low Date
Nov 15, 2018
YTD Price Change
-38999.67
YTD Gain
-100.00%
52 Week High
107400.00
52 Week High Date
Mar 14, 2013
52 Week Low
0.31
52 Week Low Date
Nov 15, 2018
52 Week Price Change
-38999.67
52 Week Gain
-100.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 26. 2018
1.27
Sep 28. 2018
1.44
2 Trading Days
12.99%
Link
Company Information
Stock Symbol
RXII
Exchange
NasdaqCM
Company URL
http://www.rxipharma.com
Company Phone
(508) 767-3861
CEO
Geert Cauwenbergh
Headquarters
Massachusetts
Business Address
257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH, MA 01752
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001533040
About

RXi Pharmaceuticals Corp. is a biotechnology company. It focuses on discovering, developing and commercializing innovative therapies based on its proprietary, new-generation RNA interference platform. RXi Pharmaceuticals proprietary therapeutic platform is comprised of novel RNAi compounds include rxRNAori and sd-rxRNA. Its clinical product candidate is RXI-109 a self-delivering RNAi compound developed for the reduction of dermal scarring in planned surgeries. RXI-109 is designed to reduce the expression of connective tissue growth factor a critical regulator of several biological pathways involved in scarring and fibrotic diseases. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Description

RXi Pharmaceuticals Corporation, a clinical-stage RNAi company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs include RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids; and a Phase I/II clinical trial in retinal scarring. It is also developing RXI-109 for the treatment of an ophthalmic indication, focusing on retinal and corneal scarring; and Samcyprone, a formulation of diphenylcyclopropenone, which is in Phase II clinical trial for the treatment of various disorders, such as warts, alopecia areata, non-malignant skin tumors, and cutaneous metastases of melanoma. In addition, the company is developing dermal scarring and wart programs with its sd-rxRNA technology. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading